161 related articles for article (PubMed ID: 32249461)
1. Analysis of lncRNA UCA1-related downstream pathways and molecules of cisplatin resistance in lung adenocarcinoma.
Zhou H; Shen Q; Fu J; Jiang F; Wang L; Wang Y
J Clin Lab Anal; 2020 Aug; 34(8):e23312. PubMed ID: 32249461
[TBL] [Abstract][Full Text] [Related]
2. lncRNA RP11-838N2.3 Promoted Cisplatin Resistance in Lung Adenocarcinoma.
Chen J; Jiang F; Hu L; Zhang F; Wang J; Huang K; Wang Y
Biomed Res Int; 2020; 2020():2806042. PubMed ID: 32626737
[TBL] [Abstract][Full Text] [Related]
3. Aberrant Long Noncoding RNAs Expression Profiles Affect Cisplatin Resistance in Lung Adenocarcinoma.
Hu L; Chen J; Zhang F; Wang J; Pan J; Chen J; Wang Y
Biomed Res Int; 2017; 2017():7498151. PubMed ID: 29279851
[TBL] [Abstract][Full Text] [Related]
4. LncRNA UCA1 promoted cisplatin resistance in lung adenocarcinoma with HO1 targets NRF2/HO1 pathway.
Shi W; Ling L; Li C; Wu R; Zhang M; Shao F; Wang Y
J Cancer Res Clin Oncol; 2023 Mar; 149(3):1295-1311. PubMed ID: 35792913
[TBL] [Abstract][Full Text] [Related]
5. Silence of lncRNA UCA1 rescues drug resistance of cisplatin to non-small-cell lung cancer cells.
Liu X; Huang Z; Qian W; Zhang Q; Sun J
J Cell Biochem; 2019 Jun; 120(6):9243-9249. PubMed ID: 30652341
[TBL] [Abstract][Full Text] [Related]
6. Low expression of PRKCDBP promoted cisplatin resistance in lung adenocarcinoma by DNMT1 and TNF‑α.
Fu J; Zhou H; Chen J; Wang Y
Oncol Rep; 2020 Oct; 44(4):1616-1626. PubMed ID: 32945503
[TBL] [Abstract][Full Text] [Related]
7. Super enhancer-LncRNA SENCR promoted cisplatin resistance and growth of NSCLC through upregulating FLI1.
Shen Q; Zhou H; Zhang M; Wu R; Wang L; Wang Y; Chen J
J Clin Lab Anal; 2022 Jun; 36(6):e24460. PubMed ID: 35500152
[TBL] [Abstract][Full Text] [Related]
8. Elevated Glutathione Peroxidase 2 Expression Promotes Cisplatin Resistance in Lung Adenocarcinoma.
Du H; Chen B; Jiao NL; Liu YH; Sun SY; Zhang YW
Oxid Med Cell Longev; 2020; 2020():7370157. PubMed ID: 32215178
[TBL] [Abstract][Full Text] [Related]
9. The Long Noncoding RNA MEG3 Contributes to Cisplatin Resistance of Human Lung Adenocarcinoma.
Liu J; Wan L; Lu K; Sun M; Pan X; Zhang P; Lu B; Liu G; Wang Z
PLoS One; 2015; 10(5):e0114586. PubMed ID: 25992654
[TBL] [Abstract][Full Text] [Related]
10. XPC inhibition rescues cisplatin resistance via the Akt/mTOR signaling pathway in A549/DDP lung adenocarcinoma cells.
Teng X; Fan XF; Li Q; Liu S; Wu DY; Wang SY; Shi Y; Dong M
Oncol Rep; 2019 Mar; 41(3):1875-1882. PubMed ID: 30628719
[TBL] [Abstract][Full Text] [Related]
11. Effect of lncRNA-BLACAT1 on drug resistance of non-small cell lung cancer cells in DDP chemotherapy by regulating cyclin D1 expression.
Ju ZS; Sun B; Bao D; Zhang XF
Eur Rev Med Pharmacol Sci; 2020 Sep; 24(18):9465-9472. PubMed ID: 33015788
[TBL] [Abstract][Full Text] [Related]
12. An inverse interaction between
Zhang Y; Yuan Y; Li Y; Zhang P; Chen P; Sun S
Epigenetics; 2019 Oct; 14(10):949-960. PubMed ID: 31144606
[No Abstract] [Full Text] [Related]
13. The long noncoding RNA HOTAIR contributes to cisplatin resistance of human lung adenocarcinoma cells via downregualtion of p21(WAF1/CIP1) expression.
Liu Z; Sun M; Lu K; Liu J; Zhang M; Wu W; De W; Wang Z; Wang R
PLoS One; 2013; 8(10):e77293. PubMed ID: 24155936
[TBL] [Abstract][Full Text] [Related]
14. miR-324-3p reverses cisplatin resistance by inducing GPX4-mediated ferroptosis in lung adenocarcinoma cell line A549.
Deng SH; Wu DM; Li L; Liu T; Zhang T; Li J; Yu Y; He M; Zhao YY; Han R; Xu Y
Biochem Biophys Res Commun; 2021 Apr; 549():54-60. PubMed ID: 33662669
[TBL] [Abstract][Full Text] [Related]
15. LncRNA RP3-326I13.1 promotes cisplatin resistance in lung adenocarcinoma by binding to HSP90B and upregulating MMP13.
Zhou H; Huang X; Shi W; Xu S; Chen J; Huang K; Wang Y
Cell Cycle; 2022 Jul; 21(13):1391-1405. PubMed ID: 35298351
[TBL] [Abstract][Full Text] [Related]
16. CircPVT1 contributes to chemotherapy resistance of lung adenocarcinoma through miR-145-5p/ABCC1 axis.
Zheng F; Xu R
Biomed Pharmacother; 2020 Apr; 124():109828. PubMed ID: 31986409
[TBL] [Abstract][Full Text] [Related]
17. Upregulation of Long Noncoding RNA (lncRNA) X-Inactive Specific Transcript (XIST) is Associated with Cisplatin Resistance in Non-Small Cell Lung Cancer (NSCLC) by Downregulating MicroRNA-144-3p.
Tian LJ; Wu YP; Wang D; Zhou ZH; Xue SB; Zhang DY; Wei YG; Liu W
Med Sci Monit; 2019 Oct; 25():8095-8104. PubMed ID: 31659146
[TBL] [Abstract][Full Text] [Related]
18. LncRNA NNT-AS1 is a major mediator of cisplatin chemoresistance in non-small cell lung cancer through MAPK/Slug pathway.
Cai Y; Dong ZY; Wang JY
Eur Rev Med Pharmacol Sci; 2018 Aug; 22(15):4879-4887. PubMed ID: 30070323
[TBL] [Abstract][Full Text] [Related]
19. FGD5‑AS1 promotes cisplatin resistance of human lung adenocarcinoma cell via the miR‑142‑5p/PD‑L1 axis.
Zhu F; Niu R; Shao X; Shao X
Int J Mol Med; 2021 Feb; 47(2):523-532. PubMed ID: 33416094
[TBL] [Abstract][Full Text] [Related]
20. Chaperonin containing TCP1 subunit 3 (CCT3) promotes cisplatin resistance of lung adenocarcinoma cells through targeting the Janus kinase 2/signal transducers and activators of transcription 3 (JAK2/STAT3) pathway.
Danni X; Jiangzheng Z; Huamao S; Yinglian P; Changcheng Y; Yanda L
Bioengineered; 2021 Dec; 12(1):7335-7347. PubMed ID: 34612768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
